1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD

X. Le, L. Hendriks, Alessandro Morabito, L. Bonanno, Isamu Okamoto, J.W. Goldman, H.A. Yu, O.T. Brustugun, Tarje Onsøien Halvorsen, Yu Jung Kim, Kristen A. Marrone, B.C. Cho, Jonathan W. Riess, Adrianus J. de Langen, Zofia Piotrowska, Helen Ambrose, Peter J. Smith, John M. Lehman, P.G. Fraenkel, Sarah B. Goldberg